Which new medicines did the FDA approve this month?

These approvals apply to specific diagnoses and patient groups, not every person with a broadly similar condition.

September’s novel approvals include Isembyld (apitegromab-mstn) for adults and children 2 and older with spinal muscular atrophy who already receive an SMN2-targeted treatment; Etcamah (camizestrant) with a CDK4/6 inhibitor for a defined ESR1-mutated form of advanced HR-positive/HER2-negative breast cancer; and Zanvastro (zilganersen) for Alexander disease in children and adults. The Aug. 26 list also includes Rasonque (daraxonrasib) for certain adults with metastatic pancreatic cancer.

These are narrow FDA indications—not universal cures—and eligibility belongs with a specialist.

Why approval month roundups mislead

A drug 'approved in September' did not start in September — approvals are the finish line of trials that ran for years, and the FDA often acts on dates set months ahead (called PDUFA dates). A roundup blurs together very different things: first-of-a-kind treatments, new uses for old drugs, and new versions of existing products.

What to do, step by step

1. Sort by type: a new active ingredient is a bigger deal than a new dose or a label expansion of a drug already sold.
2. Check the indication wording. 'Approved for X' often means a narrow slice of X — a specific subtype, age group, or patients who failed another drug first.
3. Ask when it reaches pharmacies. Approval and availability differ; manufacturing and insurance listings can lag by months.